Effects of topical administration of Y-39983, a selective Rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys

被引:148
|
作者
Tokushige, Hideki
Inatani, Masaru
Nemoto, Shingo
Sakaki, Hideyuki
Katayama, Koushirou
Uehata, Masayoshi
Tanihara, Hidenobu
机构
[1] Senju Pharmaceut Co Ltd, Res Labs, Chuo Ku, Osaka 5410046, Japan
[2] Kumamoto Univ, Grad Sch Med Sci, Dept Ophthalmol & Visual Sci, Kumamoto 860, Japan
[3] Mitsubishi Pharma Co Ltd, Discovery Technol Lab 1, Osaka, Japan
关键词
D O I
10.1167/iovs.05-1617
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PURPOSE. To elucidate the intraocular pressure (IOP)-lowering effects and associated characteristics of Y-39983, a selective Rho-associated coiled coil-forming protein kinase (ROCK) inhibitor derived from Y- 27632, in animal eyes. METHODS. Y- 39983 was compared with Y- 27632 for selectivity of ROCK inhibition by biochemical assay. The IOP was monitored by pneumatonometer in albino rabbits and cynomolgus monkeys that were given topically administered Y-39983. The total outflow facility and uveoscleral outflow were measured by two-level constant-pressure perfusion and perfusion technique using fluorescein isothiocyanate-dextran, respectively, at 2 hours after topical administration of Y- 39983 in albino rabbits. The ocular toxicologic effects of topical administration of Y- 39983 were observed in albino rabbits and cynomolgus monkeys. RESULTS. A biochemical assay showed that Y- 39983 inhibited ROCK more potently than Y-27632. In rabbits, topical administration of Y- 39983 significantly increased conventional outflow by 65.5%, followed by significant, dose-dependent reduction in IOP. Maximum IOP reduction was 13.2 +/- 0.6 mm Hg ( mean +/- SE) at 0.1% Y-39983 in rabbits. In monkeys, at 3 hours after topical administration of 0.05% Y-39983, maximum reduction of IOP was 2.5 +/- 0.8 mm Hg. No serious side effects were observed in ocular tissues except sporadic punctate subconjunctival hemorrhage during long-term topical administration of Y- 39983 four times a day (at 2-hour intervals) in rabbits or monkeys. However, punctate subconjunctival hemorrhage was not observed with administration twice daily (at a 6-hour interval) or three times a day (at 5-hour intervals). CONCLUSIONS. Y-39983 causes increased outflow facility followed by IOP reduction. Y-39983 ophthalmic solution may be a candidate drug for lowering of IOP, since it increases conventional outflow and produces relatively few side effects.
引用
收藏
页码:3216 / 3222
页数:7
相关论文
共 50 条
  • [1] Intraocular pressure-lowering effects of topical administration of Y-39983, a novel selective Rho-associated protein kinase inhibitor
    Inatani, M
    Tokushige, H
    Nemoto, S
    Tajika, T
    Uehata, M
    Tanihara, H
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2005, 46
  • [2] Effects of Y-39983, a Selective Rho-Associated Protein Kinase Inhibitor, on Blood Flow in Optic Nerve Head in Rabbits and Axonal Regeneration of Retinal Ganglion Cells in Rats
    Tokushige, Hideki
    Waki, Mitsunori
    Takayama, Yoshiko
    Tanihara, Hidenobu
    CURRENT EYE RESEARCH, 2011, 36 (10) : 964 - 970
  • [3] Effects of Rho-associated protein kinase inhibitors Y-27632 and Y-39983 on isolated rabbit ciliary arteries
    Hiroshi Watabe
    Sanae Abe
    Takeshi Yoshitomi
    Japanese Journal of Ophthalmology, 2011, 55 : 411 - 417
  • [4] Effects of Rho-associated protein kinase inhibitors Y-27632 and Y-39983 on isolated rabbit ciliary arteries
    Watabe, Hiroshi
    Abe, Sanae
    Yoshitomi, Takeshi
    JAPANESE JOURNAL OF OPHTHALMOLOGY, 2011, 55 (04) : 411 - 417
  • [5] Y-39983 downregulates RhoA/Rho-associated kinase expression during its promotion of axonal regeneration
    Yang, Zijian
    Wang, Jing
    Liu, Xiaohong
    Cheng, Yu
    Deng, Lianfu
    Zhong, Yisheng
    ONCOLOGY REPORTS, 2013, 29 (03) : 1140 - 1146
  • [6] Reduction of intraocular pressure by topical administration of an inhibitor of the Rho-associated protein kinase
    Waki, M
    Yoshida, Y
    Oka, T
    Azuma, M
    CURRENT EYE RESEARCH, 2001, 22 (06) : 470 - 474
  • [7] Y-39983, a Selective Rho-Kinase Inhibitor, Attenuates Experimental Autoimmune Encephalomyelitis via Inhibition of Demyelination
    Gao, Cong
    Huang, Li
    Long, Youming
    Zheng, Jianzheng
    Yang, Jie
    Pu, Shuxiang
    Xie, Longchang
    NEUROIMMUNOMODULATION, 2013, 20 (06) : 334 - 340
  • [8] The effects of a Rho-associated protein kinase (ROCK) inhibitor (Y39983) on human trabecular meshwork cells - a morphological and proteomic study
    Shan, Sze Wan
    Lam, Thomas Cheun
    Stamer, William D.
    Li, Hoi Lam
    Do, Chi-Wai
    To, Chi Ho
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
  • [9] Effects of Fasudil, a Rho-Associated Protein Kinase Inhibitor, on Optic Nerve Head Blood Flow in Rabbits
    Sugiyama, Tetsuya
    Shibata, Maho
    Kajiura, Sumiko
    Okuno, Takashi
    Tonari, Masahiro
    Oku, Hidehiro
    Ikeda, Tsunehiko
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2011, 52 (01) : 64 - 69
  • [10] The Ocular Hypotensive Efficacy of Topical Fasudil, a Rho-Associated Protein Kinase Inhibitor, in Patients With End-Stage Glaucoma
    Pakravan, Mohammad
    Beni, Afsaneh Naderi
    Ghahari, Elham
    Varshochian, Reyhaneh
    Yazdani, Shahin
    Esfandiari, Hamed
    Ahmadieh, Hamid
    AMERICAN JOURNAL OF THERAPEUTICS, 2017, 24 (06) : e676 - e680